Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy

Tatsuyuki Chiyoda, H. Tsuda, Hiroyuki Nomura, Fumio Kataoka, Eiichirou Tominaga, A. Suzuki, N. Susumu, Daisuke Aoki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy. Methods: We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy. Results: In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was ≥ 3 months had a higher non-PD rate than those with TFI < 3 months (86% vs 33%, p = 0.002). In addition, the median overall survival (OS) was longer for TFI ≥ 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests. Conclusion: TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.

Original languageEnglish
Pages (from-to)364-368
Number of pages5
JournalEuropean Journal of Gynaecological Oncology
Volume31
Issue number4
Publication statusPublished - 2010

Fingerprint

Platinum
Ovarian Neoplasms
Drug Therapy
Survival
taxane
Medical Records
Recurrence

Keywords

  • Epithelial ovarian cancer
  • Recurrence
  • Third-line chemotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Medicine(all)

Cite this

@article{bc96c51cac52431dbb99e0ebb7fba734,
title = "Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy",
abstract = "Purpose: At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy. Methods: We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy. Results: In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was ≥ 3 months had a higher non-PD rate than those with TFI < 3 months (86{\%} vs 33{\%}, p = 0.002). In addition, the median overall survival (OS) was longer for TFI ≥ 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests. Conclusion: TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.",
keywords = "Epithelial ovarian cancer, Recurrence, Third-line chemotherapy",
author = "Tatsuyuki Chiyoda and H. Tsuda and Hiroyuki Nomura and Fumio Kataoka and Eiichirou Tominaga and A. Suzuki and N. Susumu and Daisuke Aoki",
year = "2010",
language = "English",
volume = "31",
pages = "364--368",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy

AU - Chiyoda, Tatsuyuki

AU - Tsuda, H.

AU - Nomura, Hiroyuki

AU - Kataoka, Fumio

AU - Tominaga, Eiichirou

AU - Suzuki, A.

AU - Susumu, N.

AU - Aoki, Daisuke

PY - 2010

Y1 - 2010

N2 - Purpose: At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy. Methods: We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy. Results: In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was ≥ 3 months had a higher non-PD rate than those with TFI < 3 months (86% vs 33%, p = 0.002). In addition, the median overall survival (OS) was longer for TFI ≥ 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests. Conclusion: TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.

AB - Purpose: At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy. Methods: We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy. Results: In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was ≥ 3 months had a higher non-PD rate than those with TFI < 3 months (86% vs 33%, p = 0.002). In addition, the median overall survival (OS) was longer for TFI ≥ 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests. Conclusion: TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.

KW - Epithelial ovarian cancer

KW - Recurrence

KW - Third-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=77956131260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956131260&partnerID=8YFLogxK

M3 - Article

C2 - 20882873

AN - SCOPUS:77956131260

VL - 31

SP - 364

EP - 368

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 4

ER -